The manufacturing of medicinal products is for us not only a matter of implementing a certain technological process, but a human mission based on high standards of quality, safety and efficacy of medications
Sofia, Bulgaria, 14 June 2023 – According to the requirements of Art. 100t of LPOS and in connection with Art. 114, para. 9 of the Law on Public Offering of Securities, “Sopharma” AD announces that today, according to a decision of the Board of Directors dated 12 May 2023, the company concluded the following transaction falling within the scope of Art. 114, para. 2 of the LPOS:
Sofia, Bulgaria, June 9, 2023 - Pursuant to the requirements of Article 100t of the LPOS and in conjunction with Article 114, par. 9 of the LPOS, "Sopharma" AD hereby informs that following a request made to the parent company "Sopharma" AD by the subsidiary "Pharmalogistika" AD and the consent given by the Board of Directors on 06.06.2023, today the subsidiary concluded the following transaction falling within the scope of Art. 114 para. 3 of the Securities Act:
